A prospective randomized controlled study of panax notoginseng in the treatment of early renal injury after ESWL

doi:10.3877/cma.j.issn.1674-3253.2021.05.012

Abstract

Abstract:

Objective

To evaluate the effect of panax notoginseng in the treatment of early renal injury after ESWL.

Methods

From October 2018 to October 2019, all the patients receiving ESWL in our department were included and randomly divided into two groups, the panax notoginseng group and the control group. The paxnax notoginseng group were assigned panax notoginseng powder (2 g bid×7 d) 1 day after ESWL. The renal injury was evaluated by detecting the levels of urine kidney injury molecule-1 (KIM-1), Neutrophil gelatinase associated lipocalin (NAGL), Cystatinc (Cys-C) and serum superoxide dismutase (SOD), malondialdehyde (MDA).

Results

A total of 140 patients complied with the criteria were finally included, 70 cases in each group. The baseline characteristics of the two groups were the same. The levels of Urinary KIM-1, NAGL and Cys-C after ESWL in both groups were significantly higher than that preoperative, respectively. Meanwhile, the levels of those markers in panax notoginseng group were significantly lower than that in control group after ESWL. The serum levels of SOD decreased while the MDA levels increased in both groups significantly after ESWL. Besides, The SOD level after ESWL in panax notoginseng group was significantly higher than that in the control group, while the MDA level was significantly lower.

Conclusion

Panax notoginseng may treat early kidney injury caused by ESWL, which is worthy of clinical application.

Key words: Panax notoginseng, Traditional Chinese medicine, ESWL, Kidney injury

Guolong Liao, ying Liu, Jiani Tang, Haiyun Xiong, Jun Pang, Donggen Jiang. A prospective randomized controlled study of panax notoginseng in the treatment of early renal injury after ESWL[J]. Chinese Journal of Endourology(Electronic Edition), 2021, 15(05): 415-418.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2021.05.012

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2021/V15/I05/415

Figures/Tables 3

References 25

[1]	Basulto-Martinez M,Klein I,Gutierrez-Aceves J. The role of extracorporeal shock wave lithotripsy in the future of stone management[J].Curr Opin Urol, 2019, 29(2): 96-102.
[2]	Magalhães Luís , Nogué Ramon . Clinical use of renal point-of-care ultrasound after extracorporeal shock wave lithotripsy[J]. Ultrasound J, 2019, 11(1): 25.
[3]	Kazama I, Nakajima T. Postrenal acute kidney injury in a patient with unilateral ureteral obstruction caused by urolithiasis: A case report[J]. Medicine (Baltimore). 2017, 96(43): e8381.
[4]	李翔, 贺大林, 张林琳, 等. 黄芪提取成分对体外冲击波碎石术致肾损伤的保护作用[J]. 中华医学杂志, 2005, 85(31): 2201-2206.
[5]	赵俊龙, 姜宁, 杨佳伟, 等. 银杏叶提取物保护体外冲击波碎石术致早期肾损伤的临床研究[J]. 安徽医药, 2019, 23(1): 164-166.
[6]	宋侠. 三七皂苷药理作用研究进展[J]. 中国现代药物应用, 2017, 11(14): 174-175.
[7]	麦焕章, 旋桂香, 吴健恒. 田七在中医学上的应用和临床使用体会[J]. 中国医药指南, 2012, 10(4): 229-230.
[8]	庄高建, 胡鸿运, 杨英, 等. 基于Klotho研究三七总皂苷对大鼠肾缺血-再灌注损伤的保护机制[J]. 中国中医药信息杂志, 2018, 25(11): 31-35.
[9]	那彦群, 叶章群, 孙颖浩, 等. 中国泌尿外科疾病诊断治疗指南[M]. 人民卫生出版社, 2014版, 306-309.
[10]	谢凯, 杨为民, 杨欢, 等. X线定位体外冲击波碎石术23年15019例疗效观察[J]. 中华泌尿外科杂志, 2012, 33(8): 581-583.
[11]	王宁, 杨欢, 陈志强. 果蝇模型在肾结石研究中的应用进展[J].中华泌尿外科杂志, 2016, 37(5): 398-400．
[12]	D' Alessandro Claudia , Ferraro Pietro Manuel , Cianchi Caterina ,et al. Which diet for calcium stone patients: a real-world approach to preventive care[J]. Nutrients, 2019, 11(5), 1182.
[13]	Dzięgała Mateusz , Krajewski Wojciech , Kołodziej Anna，etal. Evaluation and physiopathology of minor transient shock wave lithotripsy-induced renal injury based on urinary biomarkers levels[J]. Cent European J Urol, 2018, 71(2): 214-220.
[14]	桂西青, 郭振宇, 孙华宾, 等. 逐步提高冲击波能量预处理对体外冲击波碎石术肾损伤的保护作用[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2008,3 (1): 62-65.
[15]	陈景秋, 邓艇, 田祖安. ESWL中的空化效应[J]. 重庆大学学报(自然科学版), 2007, 30(8): 128-132.
[16]	Clark DL, Connors BA, Evan AP, et al. Localization of renal oxidative stress and inflammatory response after lithotripsy[J]. BJU Int, 2009, 103(11): 1562-1568.
[17]	江伟东, 朱黎, 廖国龙等, 田七对高能冲击波碎石致肾损伤的保护作用[J].华南国防医学杂志, 2014, 4(28): 318-320.
[18]	王志勇, 郭利, 李红阳, 等. 尿肾损伤分子-1对单侧梗阻性肾病肾功能早期评估的价值[J]. 中国医师进修杂志, 2017, 40(11): 978-981.
[19]	Jin Y, Shao X, Sun B, etal. Urinary kidney injury molecule as an early diagnostic biomarker of obstructiveacute kidney injury and development of a rapid detection method[J]. Mol Med Rep, 2017, 15(3): 1229-1235.
[20]	Lippi Ilaria, Perondi F., Meucci V.,etal.Clinical utility of urine kidney injury molecule-1 (KIM-1) and gammaglutamyl transferase (GGT) in the diagnosis of canine acute kidney injury[J]. Vet Res Commun, 2018, 42(2): 95-100.
[21]	伍弘智. 急性肾损伤患者尿液与血液中肾脏损伤分子-1的表达及其对肾衰竭的早期诊断价值[J]. 海南医学院学报, 2015, 21(2): 215-217.
[22]	孙延慧, 王凤超. NGAL在肾损伤中的研究进展[J]. 医学理论与实践, 2014, 12(1): 1575-1577.
[23]	Siddiqi Z, Karoli R, Kaul A, et al. Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as early markers of diabetic nephropathy[J]. Ann Afr Med, 2017, 16(3): 101-106．
[24]	Neyra Javier A , Hu Ming-Chang , Minhajuddin Abu ,et al. Kidney tubular damage and functional biomarkers in acute kidney injury following cardiac surgery[J]. Kidney Int Rep, 2019, 4(8): 1131-1142.
[25]	Dzięgała Mateusz , Krajewski Wojciech , Kołodziej Anna ,et al. Evaluation and physiopathology of minor transient shock wave lithotripsy-induced renal injury based on urinary biomarkers levels[J]. Cent Eur J Urol, 2018,71(2): 214-220.

组别	例数	年龄[岁，(±s)]	BMI[kg/m²，(±s)]	结石大小[cm，(±s)]	病程[d，(±s)]	性别(例)		位置(例)
组别	例数	年龄[岁，(±s)]	BMI[kg/m²，(±s)]	结石大小[cm，(±s)]	病程[d，(±s)]	男	女	左	右
田七组	70	35.8±9.4	20.5±1.6	1.7±0.2	9.4±5.3	26	28	22	25
对照组	70	34.8±7.9	20.2±1.4	1.6±0.2	9.6±5.4	24	22	28	25
统计值		t=0.691	t=0.973	t=1.647	t=-0.331	χ² =0.161		χ² =0.361
P值		0.491	0.332	0.102	0.741	0.688		0.548

组别	例数	年龄[岁，(±s)]	BMI[kg/m²，(±s)]	结石大小[cm，(±s)]	病程[d，(±s)]	性别(例)		位置(例)
组别	例数	年龄[岁，(±s)]	BMI[kg/m²，(±s)]	结石大小[cm，(±s)]	病程[d，(±s)]	男	女	左	右
田七组	70	35.8±9.4	20.5±1.6	1.7±0.2	9.4±5.3	26	28	22	25
对照组	70	34.8±7.9	20.2±1.4	1.6±0.2	9.6±5.4	24	22	28	25
统计值		t=0.691	t=0.973	t=1.647	t=-0.331	χ² =0.161		χ² =0.361
P值		0.491	0.332	0.102	0.741	0.688		0.548

组别	例数	KIM-1			NGAL			Cys-C
组别	例数	ESWL前1 d	ESWL后3 d	ESWL后7 d	ESWL前1 d	ESWL后3 d	ESWL后7 d	ESWL前1 d	ESWL后3 d	ESWL后7 d
田七组	70	92.8±7.0	115.4±9.0	97.3±11.5	4.0±0.9	8.6±1.1	6.9±1.0	25.4±2.6	34.1±3.5	29.1±1.0
对照组	70	92.4±7.2	121.2±8.2	103.8±8.1	3.9±0.8	9.4±1.3	7.6±0.9	25.0±2.5	37.0±3.6	29.7±1.6
t值		0.290	-3.995	-3.830	0.359	-3.972	-4.236	0.819	-4.886	-2.803
P值		0.772	<0.001	<0.001	0.720	<0.001	<0.001	0.414	<0.001	00.006

组别	例数	KIM-1			NGAL			Cys-C
组别	例数	ESWL前1 d	ESWL后3 d	ESWL后7 d	ESWL前1 d	ESWL后3 d	ESWL后7 d	ESWL前1 d	ESWL后3 d	ESWL后7 d
田七组	70	92.8±7.0	115.4±9.0	97.3±11.5	4.0±0.9	8.6±1.1	6.9±1.0	25.4±2.6	34.1±3.5	29.1±1.0
对照组	70	92.4±7.2	121.2±8.2	103.8±8.1	3.9±0.8	9.4±1.3	7.6±0.9	25.0±2.5	37.0±3.6	29.7±1.6
t值		0.290	-3.995	-3.830	0.359	-3.972	-4.236	0.819	-4.886	-2.803
P值		0.772	<0.001	<0.001	0.720	<0.001	<0.001	0.414	<0.001	00.006

组别	例数	SOD（μmol/ml）			MDA（μmol/L）
组别	例数	ESWL前1 d	ESWL后3 d	ESWL后7 d	ESWL前1 d	ESWL后3 d	ESWL后7 d
田七组	70	108.6±3.9	93.3±2.7	101.9±2.2	5.3±0.6	6.7±0.7	8.0±0.5
对照组	70	110.0±4.8	91.8±3.2	099.6±3.0	5.2±0.5	6.9±0.7	8.3±0.5
t值		-1.761	3.001	5.025	1.186	-2.604	-3.686
P值		00.080	0.003	<0.0010	0.238	00.010	<0.001

Please choose a citation manager

Content to export